Please login to the form below

Not currently logged in
Email:
Password:

CRL

This page shows the latest CRL news and features for those working in and with pharma, biotech and healthcare.

Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery

Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery

In March 2021, the US Food and Drug Administration (FDA) issued Merck &Co a complete response letter (CRL) rejecting a supplemental biologics licence application (sBLA) for Keytruda (pembrolizumab) in TNBC, based

Latest news

More from news
Approximately 1 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Shanks v Unilever? Or David v Goliath? Shanks v Unilever? Or David v Goliath?

    The facts. Professor Shanks was employed as an inventor by a subsidiary of Unilever called Central Resources Limited (CRL). ... In comparison with CRL, Professor Shanks’ invention was of sufficient benefit to award him compensation.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    During 2016 the FDA issued 14 CRLs, compared to just two in 2015. ... Failure of manufacturing facilities to pass FDA inspection can unnecessarily delay patient access to novel new drugs.” The increase of CRLs seen in 2016 indicates that the use of

  • Deal Watch May 2016 Deal Watch May 2016

    The CRL refers to a manufacturing issue. ZS-9 was acquired when the company purchased ZS Pharma for $2.7bn. ... The manufacturing CRLs have been out in force and AstraZeneca is not the only company on the receiving end with OPKO receiving a CRL earlier

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...